{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T08:16:11Z","timestamp":1787904971161,"version":"build-2784847793"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim Pharma GmbH und Co. KG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.rmed.2021.106369","type":"journal-article","created":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T22:40:32Z","timestamp":1615675232000},"page":"106369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease"],"prefix":"10.1016","volume":"180","author":[{"given":"Ulrike","family":"Schmid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1316-5184","authenticated-orcid":false,"given":"Benjamin","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats O.","family":"Magnusson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Freiwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2021.106369_bib1","series-title":"OFEV\u00ae (Nintedanib): Prescribing Information","year":"2020"},{"key":"10.1016\/j.rmed.2021.106369_bib2","series-title":"OFEV\u00ae (Nintedanib): Summary of Product Characteristics","author":"European Medicines Agency","year":"2020"},{"issue":"12","key":"10.1016\/j.rmed.2021.106369_bib3","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","article-title":"Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis","volume":"365","author":"Richeldi","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2021.106369_bib4","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1136\/thoraxjnl-2016-209701","article-title":"Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension","volume":"73","author":"Richeldi","year":"2018","journal-title":"Thorax"},{"issue":"22","key":"10.1016\/j.rmed.2021.106369_bib5","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Inpulsis Trial Investigators, Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2021.106369_bib6","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","article-title":"Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS(\u00ae) trials","volume":"113","author":"Richeldi","year":"2016","journal-title":"Respir. Med."},{"issue":"26","key":"10.1016\/j.rmed.2021.106369_bib7","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis\u2013associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2021.106369_bib8","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.rmed.2021.106369_bib9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/00498254.2010.545452","article-title":"Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers","volume":"41","author":"Stopfer","year":"2011","journal-title":"Xenobiotica"},{"key":"10.1016\/j.rmed.2021.106369_bib10","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.pupt.2017.11.004","article-title":"Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis","volume":"48","author":"Schmid","year":"2018","journal-title":"Pulm. Pharmacol. Therapeut."},{"issue":"9","key":"10.1016\/j.rmed.2021.106369_bib11","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s40262-019-00766-0","article-title":"Clinical pharmacokinetics and pharmacodynamics of nintedanib","volume":"58","author":"Wind","year":"2019","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.rmed.2021.106369_bib12","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/jcph.1025","article-title":"Pharmacokinetics of nintedanib in subjects with hepatic impairment","volume":"58","author":"Marzin","year":"2018","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.rmed.2021.106369_bib13","article-title":"Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease","volume":"4","author":"Flaherty","year":"2017","journal-title":"BMJ Open Respir. Res."},{"issue":"Suppl 106","key":"10.1016\/j.rmed.2021.106369_bib14","first-page":"75","article-title":"Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS)","volume":"35","author":"Distler","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"issue":"7","key":"10.1016\/j.rmed.2021.106369_bib15","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.rmed.2014.04.011","article-title":"Design of the INPULSIS trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis","volume":"108","author":"Richeldi","year":"2014","journal-title":"Respir. Med."},{"issue":"6","key":"10.1016\/j.rmed.2021.106369_bib16","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1183\/09031936.00092309","article-title":"Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease","volume":"35","author":"Kim","year":"2010","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.rmed.2021.106369_bib17","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/thoraxjnl-2013-203843","article-title":"Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants","volume":"69","author":"Walsh","year":"2014","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.rmed.2021.106369_bib18","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.chest.2018.08.1076","article-title":"Hypersensitivity pneumonitis: radiologic phenotypes are associated with distinct survival time and pulmonary function trajectory","volume":"155","author":"Salisbury","year":"2019","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.rmed.2021.106369_bib19","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1513\/AnnalsATS.201807-443OC","article-title":"Computed tomography honeycombing identifies a progressive fibrotic phenotype with increased mortality across diverse interstitial lung diseases","volume":"16","author":"Adegunsoye","year":"2019","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"2","key":"10.1016\/j.rmed.2021.106369_bib20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"ATS\/ERS task force, standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2021.106369_bib21","series-title":"NONMEM Users Guide - Part VII Conditional Estimation Methods","author":"Beal","year":"1998"},{"issue":"5","key":"10.1016\/j.rmed.2021.106369_bib22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40495-016-0066-x","article-title":"Disease progression modeling: key concepts and recent developments","volume":"2","author":"Cook","year":"2016","journal-title":"Curr. Pharmacol. Rep."},{"key":"10.1016\/j.rmed.2021.106369_bib23","series-title":"Pharmacometrics: the Science of Quantitative Pharmacology","first-page":"547","article-title":"Developing models of disease progression","author":"Mould","year":"2007"},{"issue":"6","key":"10.1016\/j.rmed.2021.106369_bib24","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00003088-198106060-00002","article-title":"Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models","volume":"6","author":"Holford","year":"1981","journal-title":"Clin. Pharmacokinet."},{"issue":"9","key":"10.1016\/j.rmed.2021.106369_bib25","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1023\/A:1011970125687","article-title":"Automated covariate model building within NONMEM","volume":"15","author":"Jonsson","year":"1998","journal-title":"Pharmaceut. Res."},{"key":"10.1016\/j.rmed.2021.106369_bib26","series-title":"A Full Model Approach Based on the Covariance Matrix of Parameters and Covariates [abstr 2455]","author":"Karlsson","year":"2012"},{"key":"10.1016\/j.rmed.2021.106369_bib27","series-title":"Pharmacometrics: the Science of Quantitative Pharmacology","author":"Ette","year":"2007"},{"issue":"2","key":"10.1016\/j.rmed.2021.106369_bib28","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","article-title":"Perl-speaks-NONMEM (PsN)\u2014a Perl module for NONMEM related programming","volume":"75","author":"Lindbom","year":"2004","journal-title":"Comput. Methods Progr. Biomed."},{"issue":"3","key":"10.1016\/j.rmed.2021.106369_bib29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","article-title":"PsN-Toolkit\u2014a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM","volume":"79","author":"Lindbom","year":"2005","journal-title":"Comput. Methods Progr. Biomed."},{"issue":"2","key":"10.1016\/j.rmed.2021.106369_bib30","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J."},{"issue":"3","key":"10.1016\/j.rmed.2021.106369_bib31","doi-asserted-by":"crossref","first-page":"1900161","DOI":"10.1183\/13993003.00161-2019","article-title":"Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases","volume":"54","author":"Wollin","year":"2019","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.rmed.2021.106369_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-028150","article-title":"Rate of normal lung function decline in ageing adults: a systematic review of prospective cohort studies","volume":"9","author":"Thomas","year":"2019","journal-title":"BMJ Open"},{"issue":"Suppl 60","key":"10.1016\/j.rmed.2021.106369_bib33","article-title":"Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis","volume":"48","author":"Schmid","year":"2016","journal-title":"Eur. Respir. J."},{"issue":"Suppl 1","key":"10.1016\/j.rmed.2021.106369_bib34","article-title":"Relationship between nintedanib exposure, clinical efficacy and adverse events in patients with idiopathic pulmonary fibrosis (IPF)","volume":"43","author":"Schmid","year":"2016","journal-title":"J. Pharmacokinet. Pharmacodyn."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611121000755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611121000755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:18:32Z","timestamp":1760617112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611121000755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":34,"alternative-id":["S0954611121000755"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2021.106369","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2021.106369","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106369"}}